Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.

Treatment of Community-Acquired Pneumonia in Korea

Article information

J Korean Med Assoc. 2007;50(10):886-893
Publication date (electronic) : 2007 October 31
doi : https://doi.org/10.5124/jkma.2007.50.10.886
Kyong Ran Peck, MD
Division of Infectious Diseases, Syunkyunkwan University School of Medicine, Korea. krpeck@skku.edu

Abstract

Community-acquired pneumonia (CAP) still remains one of the most important causes of morbidity and mortality. Improving the care of patients with CAP has been the focus of many different organizations, and several guidelines have been published in the United States and Europe. When the patients are treated according to the guidelines, there are beneficial effects in outcome. Empirical treatment should depend on the regional epidemiological information on the pathogen distribution and their antimicrobial resistance. Therefore, the guidelines from other countries could not be directly applied to the treatment of CAP in Korea. Inappropriate empirical treatment has been related with treatment failure. Therefore, physicians should be aware of the recent epidemiological data on antimicrobial resistance of the most common pathogens in order to choose the active agents against pneumococcus and atypical pathogens for the treatment of CAP.

Keywords: Community-acquired pneumonia; Treatment; Streptococcus pneumoniae; Atypical pneumonia

References

1. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolome M, Balanzo X. Epidemiology of community acquired pneumonia in adults: a population-based study. Eur Respir J 2000. 15757–763.
2. Gutierrez F, Masia M, Mirete C, Soldan B, Rodriguez JC, Padilla S, Hernandez I, Royo G, Martin-Hidalgo A. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006. 53166–174.
3. Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Kleemola M, Koskela M, Leinonen M, Ronnberg PR, Saikku P, Sten M, Tarkiainen A, Tukiainen H, Pyorala K, Makela PH. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis 2001. 321141–1154.
4. Kim MJ, Cheong HJ, Sohn JW, Shim HS, Park DW, Park SC, Woo JH, Kang JM, Kim YK, Shin WS, Kim YR, Lee HJ, Kim JH. A Prospective Multicenter Study of the Etiological Analysis in Adults with Community-Acquired Pneumonia: Legionella, Leptospira, Hantaan virus and Orientia tsutsugamushi. Korean J Infect Dis 2001. 3324–31.
5. Sohn JW, Park SC, Choi YH, Woo HJ, Cho YK, Lee JS, Sim HS, Kim MJ. Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study. J Korean Med Sci 2006. 21602–607.
6. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, Ki HK, Oh WS, Suh JY, Peck KR, Lee NY, Yang Y, Lu Q, Chongthaleong A, Chiu CH, Lalitha MK, Perera J, Yee TT, Kumarasinghe G, Jamal F, Kamarulzaman A, Parasakthi N, Van PH, Carlos C, So T, Ng TK, Shibl A. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004. 482101–2107.
7. Woo JH, Kang JM, Kim YS, Shin WS, Ryu JH, Choi JH, Kim YR, Cheong HJ, Uh ST, Park CS, Chung MH, Chung KS, Lee CJ, Ryu J. A Prospective Multicenter Study of Community-acquired Pneumonia in Adults with Emphasis on Bacterial Etiology. Korean J Infect Dis 2001. 331–7.
8. Arancibia F, Ewig S, Martinez JA, Ruiz M, Bauer T, Marcos MA, Mensa J, Torres A. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000. 162154–160.
9. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999. 115462–474.
10. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004. 164502–508.
11. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007. 44S2. S27–S72.
12. Choi KM, Yeon SI, Shin JS, Yong DE, Lee KW, Kim DS. Serotype and Antimicrobial Susceptibility of Streptococcus pneumoniae. Infect Chemother 2006. 38179–185.
13. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998. 422375–2379.
14. Piroth L, Martin L, Coulon A, Lequeu C, Duong M, Buisson M, Portier H, Chavanet P. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob Agents Chemother 1999. 432484–2492.
15. Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, Lee K, Lee NY. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. Antimicrob Agents Chemother 2007. 51453–460.
16. Choo EJ, Kwak YG, Lee MS, Jeong JY, Choi SH, Kim NJ, Kim YS, Woo JH, Ryu J. In vitro Antimicrobial Activity of Cefcapene against Clinical Isolates. Infect Chemother 2005. 37133–137.
17. Song JY, Jo YM, Choi WS, Kee SY, Park CW, Hwang IS, Hyun JJ, Sohn JW, Lee CG, Cheong HJ, Kim WJ, Kim MJ. In Vitro Activity of Cefditoren against Respiratory Pathogens. Infect Chemother 2005. 37138–143.
18. Kwak YG, Choo EJ, Park SJ, Lee JE, Jeong JY, Choi SH, Kim NJ, Kim YS, Woo JH, Ryu J. In vitro antimicrobial activity of cefditoren against Streptococcus pneumoniae and Haemophilus influenzae clinical isolates. Korean J Med 2007. 7268–73.
19. Anderson KB, Tan JS, File TM Jr, DiPersio JR, Willey BM, Low DE. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003. 37376–381.
20. Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, Beekmann S. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005. 41139–148.
21. Ho PL, Tse WS, Tsang KW, Kwok TK, Ng TK, Cheng VC, Chan RM. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001. 32701–707.
22. Chung MH, Shin WS, Kim YR, Kang MW, Kim MJ, Jung HJ, Park SC, Pai H, Choi HJ, Shin HS, Kim EC, Choe KW, Kim S, Peck KR, Song JH, Lee K, Kim JM, Chong Y, Han SW, Lee KM. Etiology of Community-Acquired Pneumonia Surveyed by 7 University Hospitals. Korean J Infect Dis 1997. 29339–359.
23. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002. 341607–1612.
24. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, Luh KT. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006. 61903–908.
25. Yoon YS, Lee HJ, Yoon HI, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005. 91215–1219.
26. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000. 1601399–1408.
27. Hagberg L, Carbon C, van Rensburg DJ, Fogarty C, Dunbar L, Pullman J. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respir Med 2003. 97625–633.
28. Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003. 57377–384.
29. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004. 54515–523.
30. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP 3rd, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006. 144415–420.
31. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003. 1231503–1511.
32. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999. 1592562–2572.
33. Kolditz M, Halank M, Hoffken G. Monotherapy versus Combination Therapy in Patients Hospitalized with Community-Acquired Pneumonia. Treat Respir Med 2006. 5371–383.
34. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006. CD003344.
35. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005. 49760–766.
36. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. Jama 1998. 2791452–1457.
37. Jay SJ, Johanson WG Jr, Pierce AK. The radiographic resolution of Streptococcus pneumoniae pneumonia. N Engl J Med 1975. 293798–801.
38. Mittl RL Jr, Schwab RJ, Duchin JS, Goin JE, Albeida SM, Miller WT. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994. 149630–635.
39. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003. 37752–760.
40. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. Jama 2003. 2902588–2598.
41. Song JH, Jung SI, Ki HK, Shin MH, Ko KS, Son JS, Chang HH, Kim SW, Lee H, Kim YS, Oh WS, Peck KR, Chongthaleong A, Lalitha MK, Perera J, Yee TT, Jamal F, Kamarulzaman A, Carlos CC, So T. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004. 381570–1578.
42. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000. 90223–229.
43. Waterer GW, Buckingham SC, Kessler LA, Quasney MW, Wunderink RG. Decreasing beta-lactam resistance in Pneumococci from the Memphis region: analysis of 2,152 isolates From 1996 to 2001. Chest 2003. 124519–525.
44. Capelastegui A, Espana PP, Quintana JM, Gorordo I, Ortega M, Idoiaga I, Bilbao A. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004. 39955–963.
45. Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001. 110451–457.

Article information Continued

Copyright © 2007 Korean Medical Association

Table 1

Empirical antimicrobial therapy for community-acquired pneumonia

Table 1

Abbreviation: MAC, macrolide; FQ, fluoroquinolone; AG, aminoglycoside

Table 2

Antimicrobial therapy for specific pathogens

Table 2

Abbreviations: MIC, minimal inhibitory concentration; FQ, fluoroquinolone; ESBL, extended spectrum β-lactamase; AG, aminoglycoside; TMP-SMX, trimethoprin-sulfamethoxazole